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ABSTRACT

BACTERIA ANALYSIS BY USING A SUPERVISED MACHINE LEARNING ALGORITHM
BASED ON DROPLET MICROFLUIDICS

By
Yulder Daniel Angarita Marmolejo
August 2020

Dissertation supervised by Dr. Melikhan Tanyeri
Sepsis is a major medical problem and massive resources have been invested in developing
and evaluating alternative treatments. Statistics indicate that sepsis causes between one third and
one half of all hospital deaths in the United States. Sepsis has a high impact on health care in the
US, with direct sepsis costs in 2009 exceeding $15.4 billion. A research study found that a 1-hour
delay in appropriate antimicrobial care resulted in a 7% - 10% rise in mortality. Several professional
societies seek to reduce sepsis mortality by targeting the timely use of diagnostic tests and
antimicrobial therapy. The diagnostic instruments available to clinicians to identify the suspected
pathogen do not make a timely intervention possible. Up to 5 days of incubation are needed for
blood cultures, the majority of bacteria being detected after 12–48 h. Therefore, fast and simple
techniques are required for rapid bacterial cell detection and quantification. By using droplet
microfluidics and a machine learning algorithm, the objective of this study was to propose a
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technology that analyzes images of bacterial cells by image processing and Support Vector
Machines algorithm to classify droplets containing the bacteria. The accuracy of the proposed
technology was 97.2 % for a trained SVM model and with the complete identification and
classification of droplets.
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INTRODUCTION

1.1

Sepsis
Sepsis represents a major medical problem and enormous resources have been invested in the

development and evaluation of alternative treatments. Sepsis is a complex disorder which occurs as a
dysregulated reaction to an infection and is correlated with severe failure of organ(s) and a significant risk
of death. Bacterial infections are one of the causes of sepsis and it is crucially important to detect presence
of bacteria in patient samples. Sepsis is high incidence and the condition represents one of the leading
causes of death worldwide. Sepsis is indeed a critical public health concern with large economic
repercussions. A considerable amount of research and improved clinical procedures have increased the
speed of sepsis detection and diagnosis over the past 30 years. In 2016, a new definition was developed to
further refine this process, with a greater focus on organ dysfunction recognition in the context of
infection(1). In 2017, the WHA and the WHO declared sepsis a global health concern, and adopted a
resolution to strengthen sepsis prevention, diagnosis and management(2). While sepsis is a global problem,
most of the available literature and evidence come from high-income countries overwhelmingly. In every
health care system, there is need for more research and a greater understanding of sepsis, particularly to
better identify patient populations and personalize treatments. It is also critical that in future, low-income
and middle-income countries are not ignored by global research and quality-improvement agendas on
sepsis.

1.2

Incidence

In any given country the actual occurrence of sepsis is uncertain. The reported incidence depends
on the particular term used, the infecting organism, the notification process (such as the use of the
International Disease Classification 9 coding systems) and the provision of either organ support or
critical care. Such factors lead to substantial variations between estimates and distinct geographical
locations. Most of the data documenting the occurrence of sepsis are from high-income countries
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where sepsis contributes with 2·8 million deaths per year(3). In 2001, Angus and colleagues
estimated that the frequency of severe sepsis in the United States was more than 750,000 cases per
year (300 cases per 100,000 population), which is equal to 2.26 cases per 100 hospital
discharges(4). A reflective analysis of over 2,9 million adults who were admitted to 409 US
hospitals in 2014, clinical sepsis indicators were found in 6% of hospitalized patients, 21% of
whom died in hospital or were discharged to hospice. In 35% of all hospitalizations which
culminated in death, sepsis was present(5). In the United Kingdom, the recorded incidence of
sepsis in samples originating from ICU is 27% of all ICU admissions, while the frequency in the
United States is 12%(6). This disparity could be explained in part by the markedly higher number
of ICU beds available in the United States than in the United Kingdom, and therefore by the
different triage patterns and admission requirements(7). Generally, the incidence of sepsis is likely
to be significantly under-reported and with an aging population the incidence will keep rising.
Perhaps, the true scale of the problem is far higher than what has been published. According to
statistics, sepsis causes between a third and a half of all hospital deaths in the USA(8). While these
statistics reflect the incidence of sepsis in high-resource countries, the majority of sepsis deaths
occur in low-resource countries where it is difficult to accurately determine the exact incidence of
sepsis. The available evidence indicates that around 90 percent of the world's deaths from chest
infections occur in low-resource settings(3) and approximately 70 percent of the 9 million deaths
from neonatal and child chest infections are sepsis-related, and most cases occur in Asia and
Africa(9). Sepsis can be originated from any infectious organism and consequently, the spectrum
of syndrome presentations is very wide and varies considerably across geographic regions. Sepsis
may arise from community settings or may result from a hospital or other health care facility stay;
furthermore, approximately 80 percent of cases of hospital-treated sepsis arise in the community.
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The most common infection site contributing to sepsis is the lung (64% of cases), followed by the
abdomen (20%), bloodstream (15%), and renal and genitourinary tract (14%)(10).
It is very possible that a baseline mortality from sepsis is simply the nature of the disease itself
and, despite our best efforts to understand, diagnose and manage the disorder, it is unrealistic to
expect death rates to drop to zero in reality. Amid enhanced diagnostic procedures and vigorous
clinical measures, sepsis-related mortality remains high(11). Patients surviving a sepsis episode
can face prolonged hospital stay and long-term health consequences(12). The effect of sepsis on
healthcare in the US is high, with the costs directly linked to sepsis exceeding $15.4 billion in
2009(13). A 1-h delay in adequate antimicrobial therapy results in mortality increases of 710%(14). Inappropriate initial therapy in sepsis patients is associated with a 5-fold reduction in
survival(15). The Surviving Sepsis campaign, an international collaborative effort by several
professional societies with the objective of reducing sepsis mortality, aims the timely use of
diagnostic testing and antimicrobial therapy administration. For a variety of reasons, the diagnostic
tools available to clinicians to identify the responsible pathogen do not facilitate timely
intervention(16). Blood cultures (BCs) necessitate up to 5 days of incubation, most bacteria being
detected after 12–48 h of incubation. Guidelines recommend a minimum of 2 sets of BCs per septic
episode with at least 40 mL of blood collected in adults but lower blood volume in children and
neonates. Up to 2 additional BC sets may further optimize BC sensitivity(17). Approximately 40
to 60% of severe sepsis or shock patients have a microbiologically documented infection. Sepsis
would remain only clinically suspected in a substantial proportion of patients, increasing the risk
for a non-infectious cause (i.e. extreme systemic inflammatory response syndrome)(18). Phua and
colleagues published on a broad retrospective patient cohort study (n = 1,001) with serious sepsis
ICU admission and compared the characteristics and outcomes of culture-negative versus culture-
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positive episodes. Their results showed that culture-negative patients had shorter hospital stays
and lower ICU mortality and hospital mortality (35.9% versus 44.0%, P = 0.01) than culturepositive patients(19). BC's failure to produce a causative organism could be due to a number of
reasons such as previous antibiotic coverage, which could result in non-viable organisms. While
guidelines suggest collection of BC before antimicrobial administration, the regularity with which
this occurs is highly variable, with studies showing that 28%-63% of patients received antibiotics
before collection of BC(20). False-negative blood may also occur due to the presence of noncultivable or fastidious bacteria in the environment of sepsis cultures. Sepsis may also occur due
to nonbacterial pathogens, such as viral or fungal species. De Prost et al. noted that some patients
with culture-negative sepsis could have lower levels of procalcitonin and positive viral detection
in respiratory specimens(18). In addition to false-negative BC, the false-positive BC is also a cause
of concern. BC may become contaminated during the specimen collection process due to errors.
Typical contaminants include skin flora such as coagulase-negative staphylococci, α-hemolytic
streptococci, corynebacterial, and Bacillus species. The negative effect of contaminated BC can
be substantial, resulting in unnecessary antimicrobial treatment and diagnostic procedures and
prolonged hospitalization with an average cost of $8,000 - $25,000 per episode. For a negative
outcome, BC may need up to 5 days of incubation and suffer from limited sensitivity. Usually BC
bottles are incubated in automated devices that track growth in real time. Positive BC bottles are
withdrawn from the instrument and gram-stained, and the result is usually communicated as a
critical value to the clinician, enabling the clinician to narrow down treatment. Laboratories not
staffed 24/7 may further delay reporting of positive BC due to insufficient staffing. Significant
increases in mortality (10.1% vs 19.2%) were demonstrated by Barenfanger et al. when positive

4

BC Gram stains were delayed by > 1 h(21). Positive Gram stain results must be reported promptly
but may not always be feasible in small laboratories and community hospitals.
1.3

Methods to detect and quantify bacteria in Blood Samples
More recently, laboratories have adopted probe-based multiplex PCR technologies that allow

bacteria to be quickly identified in positive BC bottles. These panels are able to identify the most
commonly isolated pathogens within 1–3 h. Such panels can also detect resistance markers such
as mecA and KPC that would direct treatment choices for a full day or two before results of routine
susceptibility testing are accessible(22). The use of these panels has been shown to have a huge
positive impact on patient management, including a decrease in intensive care unit (ICU) stay and
30-day mortality, although a positive BC is still needed(23).
For more than 2 decades, molecular diagnostic research has revolutionized the field of clinical
microbiology. Use of detection strategies for DNA and RNA has served to nearly eliminate the
role of traditional routine culture for viral pathogens. For instance, cultures for cytomegalovirus
usually required 21 days of tissue culture incubation, but the results are typically available within
hours using molecular methods. The implementation of bacterial pathogen detection technologies
has advanced at a slower pace, in part due to the difficulties of separating typical bacterial flora
from pathogens. After culture amplification, the role of Nucleic Acid Amplification Tests
(NAATs) in advancing sepsis detection has been largely limited to identifying pathogens from BC
bottles. NAAT-based research is promising due to the potential for high sensitivity and the ability
to detect non-cultivable or non-viable species due to previous antibiotic treatment. One of BC's
primary limitations is the low circulating organism load (1–10 cfu / mL) during a septic
episode(24). However, Bacconi et al. determined by using culture methods that 103 or 104 GC
(genome copies)/mL of bacteria were present in the blood (25).
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The first tool approved by the FDA for direct bloodstream detection of a bacterial or fungal
pathogen was the T2Candida (T2C) assay (T2 Biosystems). Invasive candidiasis remains a
diagnostic problem for laboratories, with BC being negative in 50% of confirmed and probable
invasive candidiasis cases(26). There are currently a range of tools available to identify pathogens
directly from the blood; however, many of these are actually not FDA-approved for use in the US,
but some have approvals in Europe such as:
1.3.1

LightCycler SeptiFast
This system (Roche Molecular System) is an automated platform that can detect 19

bacterial and fungal pathogens using multiplexed PCR coupled with probe hybridization and DNA
melt curve analysis using 1.5 mL of whole blood. The pathogen identification is possible in 3.5–5
hours with subsequent detection of mecA gene associated with methicillin resistance in
Staphylococcus species. This tool Is capable of carrying out a semi-quantitative analysis which
may be useful in determining the value of positive results(27).
1.3.2

MagicPlex Sepsis
The MagicPlex Sepsis instrument (Seegene) is sensitive enough to detect more than 90

different bacteria and fungi along with methicillin and vancomycin resistance, by using multiplex
PCR from 1 mL of whole blood within 3 h. Nevertheless, only a limited subset of the 90
bacteria/fungi are identified to the species level(24).
1.3.3

VYOO
The VYOO Rapid Pathogen Identification System (Analytik Jena Gmbh) uses a

combination of DNA amplification preceded by an electrophoresis-based analysis to detect 34
bacteria and 7 fungi using a 5 mL sample volume of whole blood. Moreover, the system also
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identifies 5 different resistance markers, giving information on methicillin resistance, vancomycin
resistance, and the existence of at least 2 types of β-lactamases of extended spectrum(24).
1.3.4

PLEX-ID
PLEX-ID is a novel technology that incorporates PCR amplification and electrospray

ionization-mass spectrometry to identify pathogens directly in clinical specimens. This tool could
detect and identify up to 800 different gram-positive and gram-negative bacteria, fungi and 4
markers of resistance: mecA, vanA, vanB, and blaKPC. Such markers provide information
concerning resistance to methicillin, vancomycin, and carbapenem. The method aims the rRNA
genes and other conserved regions of the bacterial and fungal genomes by using broad-range PCRs
followed by amplicon analysis by ESI-MS (electrospray ionization mass spectrometry). Pathogen
detection is enabled by assessing the base composition of the amplified sequences instead of
evaluating the sequence itself followed by comparing the base composition to a database. The
system uses 5 mL of whole blood to get a response within 6 hours(24).
1.3.5

SepsiTest
SepsiTest (Molzym Molecular Diagnostics) amplifies bacterial 16S rRNA and fungal 18S

rRNA, allowing more than 345 bacteria and 13 fungi (Sinha) to be identified. This is followed by
Sanger sequencing and BLAST analysis for identification. The test consists of several steps and
requires 1 mL of whole blood and can take 8 – 12 hours. The device still fails to detect any
resistance markers. It can also be used to detect bacteria from other sterile fluids(24).
1.4

Methods of Quantification in Microbiology
In the majority of microbiological studies, quantification of bacterial cells is crucial; hence,

fast and simple techniques are required. The distinction between viable and nonviable microorganisms is significant. Within aggregates, viable microorganisms are usually present.
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Sometimes a mixture of bacteria is counted as a single bacterium by using the normal microbial
counting system. The term CFU has also been used to denote viable bacteria that are measured by
calculating the number of observable colonies on an agar-platform. Bacteria are never uniformly
dispersed in samples; therefore, quantitative outcomes can often be poor, irreproducible,
particularly in small samples.
1.5

Culture Based Methods
Culture-based approaches have been the oldest techniques for identifying microorganisms,

including pathogenic strains. This approach provides a verified result on the existence of a single
pathogen. It is observed that the performance rate is high and that these approaches are costeffective. However, the biggest drawback in the culture-based method is slow growth, which
means that excess time is lapsed to produce the final result, which may turn out to be fatal. Growing
bacteria in liquid medium or agar plates requires long processing times, typically taking up to 1824 hours to confirm and quantify growth. It is vital for culture methods to obtain a growth curve
(OD vs. Time) to determine several time points within the bacterial log phase, which corresponds
with the linearity of the curve as displayed in figure 1.1a, b. After calculating the dilution factor,
an aliquot of each time point is collected from the incubated bacterial solution to conduct both
absorbance measurements and agar plating. The dilution factor is acquired by making several
dilutions from the original bacterial suspension. Each dilution is plated on agar until a countable
number of colonies are formed (30 – 300) and each distinct colony represents an individual viable
bacterial cell. The number of bacteria per mL (CFU) is determined by the total number of colonies
times total dilution factor per volume of culture plate. Finally, a curve is plotted by using the OD
measurements and the CFU data based on each time point as shown in figure 1.1 d, e, f. The linear
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regression of the curve is used to determine the concentration of new bacterial suspensions by
taking their respective OD measurements.

Figure 1.1. Culture Method. a) and d) show the process to obtain bacterial growth curve and c) represents the time points in the
curve. d) and e) represents the absorbance measurements of the dilutions. f) represents the CFU data from the dilutions.

1.6

Immunoassays
Immunoassays are easy to carry out and produce quick results. Moreover, immunoassays are

usually performed before going directly into a PCR based process. The ELISA is one of the most
commonly used immunoassays to date. Purity of the antibody plays a crucial role in the
effectiveness of immunoassays(28). Besides purity, another element influencing the assay is the
antibody specificity. Polyclonal antibodies have polyvalence (multiple epitopes to bind with). This
can influence the reaction, resulting in low specificity and sensitivity; therefore, it could potentially
generate false positive outcomes. The use of several substrates in ELISA has a significant benefit
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as the substrates directly link to the corresponding conjugates and produce coloration that can be
read by a plate reader. Nonetheless, one of the drawbacks is that antibody interaction is very
complex and contamination in the intermediate stages can lead to false positive results. In the
course of time, ELISA methodologies have been changed to suit new experiments. Blocking
ELISA was developed using E. Coli O157:H7 LPS as antigen. Such modification provides a more
sensitive result than normal ELISA in the detection of pathogens. Indirect ELISA has been used
in both cattle serum and human serums to detect anti-O157 antibodies. Nonetheless, due to crossreactivity the chances of the outcome being false positive are higher(29).
1.7

Polymerase Chain Reaction (PCR) Based Methods
In 1985, Kary Mullis developed PCR, which is one of the seminal discoveries in recombinant

DNA technology. The concept behind PCR is to amplify and analyze the genes of various
pathogens; therefore, different primers have been created for each target gene. In general, the main
advantage of PCR is that the process is rapid and sensitive. In fact, PCR is faster than the culturebased methods and immunoassays. The amplified product can be obtained as quickly as 30
minutes, and it has become much easier to differentiate between strains as multiple primer pairs
are used. PCR has emerged as a very promising method for the detection of pathogen genes;
however, there are certain drawbacks. Cell lysis, nuclear acid extraction, cross contamination and
failure to react due to the presence of inhibiting agent or competing DNA from non-target cells are
some of the difficulties. This can lead to inconsistent outcomes and adversely affect the use of
PCR in diagnostic applications. PCR methods can not differentiate live from dead cells, therefore
does not report pathogen viability. The main disadvantage of all PCR detection methods is that
binding of non-specific double-stranded DNA sequences may generate false positive signals. Thus,
well-designed primers that don't amplify non-target sequences are very critical.
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1.8

Biosensors
Biosensors are one of the newest detection platforms, some of which have enhanced

detection limits that greatly minimize and mitigate the shortcomings of PCR-based techniques(28,
30). Biosensors used for pathogen detection have three main components: a bio-probe-functional
sensor platform that gives recognition specificity, a transduction platform that produces a
measurable signal in the event of target analyte capture, and an amplifier that enhances and
processes the signal to provide a quantitative estimation of the captured analytes. The key benefit
of biosensors is that they can detect pathogens with high specificities and sensitivity at low
detection limits, but biosensors may need extremely sensitive and costly instruments with
compatible computer software to produce accurate results.
1.9

Other Detection Methods
DNA microarray has become important today and has been a useful tool due to its speed,

sensitivity and specificity. Several pathogens such as B. cereus, E. coli, L. monocytogenes, P.
aeruginosa, S. enterica, S. aureus, V. parahaemolyticus and, C. freundii were detected by using
this approach. DNA microarrays can differentiate between bacterial species with high homology.
For instance, because of the high homology at DNA level, ITS regions of five Bacillus sp. (B.
anthracis, B. cereus, B. thuringiensis, B. mycoides and B. weihenstephanensis) were difficult to
differentiate. However, it was possible to detect them by using DNA microarray(31).
Ultrafiltration (UF), Immunomagnetic assays (IMS), Immunochromatic assays (ICA), and
Flow Cytometry (FC) are several of the traditional approaches. Ultrafiltration has been described
as an efficient procedure for concentrating and recovering microbes from large quantities of water
and wastewaters. Due to their very small pore sizes, UF membranes can simultaneously
concentrate viruses, bacteria and parasites on the basis of size exclusion. The UF-based technique
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included hollow-fiber UF as the primary stage for microbes concentration and then membrane
filtration for bacterial culture assays (32). Conventional IMS technique uses an external source to
catch magnetic particles against the side of the test tube resulting in poor results due to high
background microflora(33). ICA has been a useful, quick, easy, highly sensitive, specific method
and does not require expensive equipment or reagents; however, its success is highly dependent
on the specificity of the antibodies. FC is a responsive analytical technique which can quickly track
bacterial physical conditions. High sample size and precision, measurement of thousands of cells
per second, and the possibility of cell sorting are the principal advantages of flow cytometry.
However, this approach is expensive and because these instruments are sophisticated, especially
the laser-based cell sorter, skilled operators are usually required to obtain optimum or at least
acceptable performance(34).
1.10 Microfluidic Devices as a Potential Platform for Detection and Quantification of
Bacteria
Microfluidics has shown tremendous potential in developing biotechnology applications by
using small sample sizes, fast reaction times, parallelization and sample-relevant manipulation of
fluids(35). By proving an effective performance of a wide range of functions in biotechnology
laboratories, including sequencing of DNA and RNA, antimicrobial resistance screening, and drug
discovery, microfluidic systems have revolutionized the experimental biology and biomedical
research methods(36). Droplet microfluidics has enabled high-performance, highly parallel
microfluidic assays which can generate millions of data points for a specific sample/assay.
Analysis of big data, especially large numbers of images, needs intense computational resources,
advanced image processing techniques, and high-throughput analysis methods such as machine
learning. Machine learning is a subfield of Artificial Intelligence (AI) that enables computers to
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learn without explicit programming. In this study, we propose a technology that analyzes images
of individual microdroplets generated by a microfluidic platform and classify droplets containing
bacterial cells as full and the rest of the droplets as empty by using image processing and machine
learning algorithms. This technology can be used to quantify bacteria concentration within a fluid
sample for a number of applications in clinical diagnostics, microbiology, and food industry. In
chapter 2, we explain that the probability of encapsulation of a given number of cells in droplets
is calculated by the Poisson distribution, where  is the number of cells in a droplet and  is the
average number of cells per droplet volume. The original concentration of the bacterial suspension
had to be obtained using culture methods (see figure 1.2 a, b, c) as well as the average droplet
volume of the total droplets produced by the microfluidic device (see figure 1.2 d, e, f, g). As a
result, both results were used to determine the  value. In chapter 3, we describe our algorithm,
which was named Intensive-based Algorithm (IBA), to classify droplets by using major axis
length, perimeter, and circularity droplet properties (see figure 1.2 d, e, h). We selected a squared
region around the centroid of each droplet, to calculate the mean and median of pixel intensity. As
a consequence, IBA classified efficiently full and empty droplets. In addition, a model was trained
by using Support Vector Machines algorithm to perform droplet classification (see figure 1.2 d, e,
i).
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Figure 1.2. Schematic Diagram. a) and b) represent the culture method process to obtain bacterial suspension concentration. c)
and d) display droplet microfluidic process. e) represents the averaged droplet size to calculate averaged droplet volume. f) and
g) show the two classification methods.

2
2.1

MICROFLUIDICS
Droplet Microfluidics
Microfluidics is the field of study in which micrometer-scale network of channels, reservoirs

and valves are utilized to drive and manipulate fluids. It emerged in the early 1990s from
microanalytical methods and microelectronic circuits. Novel microfluidic fluid handling
techniques have been developed with applications in the medical and biotechnology fields as well
as in materials science and chemistry. Microfluidics has contributed significantly to the expansion
of microbial ecology by enabling scientists to study the activities of microbes in highly controlled
microenvironments. Droplet-based microfluidics is a subfield of microfluidics where an aqueous
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phase is segmented into individual droplets within an immiscible carrier fluid (generally mineral
or fluorinated oil) to encapsulate cells, organic molecules and reagents. Cell encapsulation
provides significant benefits for microenvironmental control and sample processing. Microfluidic
systems provide an ideal platform for cell encapsulation as the droplet size is typically comparable
to that of cells. The most common technique of encapsulating cells uses microfluidic channel
geometries that combine co-flowing water and oil phases, where the water phase is dispersed into
the oil phase and breaks into discrete water droplets. Using the common geometries such as Tjunctions, flow-focusing or co-flowing intersections (see Figure 2.1), the formation of droplets can
be precisely regulated by adjusting the differential volumetric flow rates of the immiscible fluid
phases(37).

Figure 2.1. Microfluidic geometries for droplet generation.

Methods of cell encapsulation use either passively or actively formed droplets. Passive droplet
generation takes place through the use of an external pressure sources such as syringe and pressuredriven pumps. On the other hand, active droplet production occurs with the application of an active,
short-duration pressure source. Figure 2.2 shows a typical example of passive encapsulation where
cells are encapsulated within individual droplets formed using a flow focusing geometry.
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Figure 2.2. Passive cell encapsulation

Because the number of cells per droplet can have a substantial effect on the viability of a particular
process, it is highly desirable to have a control measurement. For instance, the apparent reaction
kinetics may double when two cells rather than one are encapsulated in a droplet(37). In situations
where encapsulated cells are both abundant and considerably smaller than droplets (e.g. with
encapsulated micron-sized bacteria), the number of cells per droplet can fairly be presumed to be
indicative of the volumetric concentration of cells(38). When cells are randomly distributed in an
aqueous solution, Poisson statistics determine the number of cells per encapsulated volume. In the
case of suspended cells moving through microfluidic channels, the spatial distribution and
therefore the timing of their arrival at the droplet forming site is essentially random for passive
encapsulation. If cells are randomly entering the water-oil interface, the average cell arrival rate is
known, and the arrival of individual cells occurs independently of other cells; then the probability
of encapsulating a specific number of cells is given by the Poisson distribution:
𝑝(𝜅, 𝜆) =

𝜆𝜅 𝑒 −𝜆
𝜅!
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(2.1)

where  is the number of cells in a droplet and  is the average number of cells per droplet volume.
Additionally, Collins et al. (2015) defined  as the ratio between the volume fraction of cells in
the pre-encapsulation solution 𝜙s and that of a droplet containing one cell, defined as 𝜙𝑑 ≡

𝑉𝑐
𝑉𝑑

(2.2), where the average cell and droplet volume 𝑉𝑐 and 𝑉𝑑 are constant for given oil-water flow
rates and channel geometry. Hence,  can be described as  =
fraction 𝜙𝑠 ≪ 1 (𝑖. 𝑒. cells are sparsely distributed), 𝜙𝑠 =

𝜙𝑠
𝜙𝑑
𝑄𝑐
𝑄𝑓

(2.3), where cellular volumetric
(2.4), and 𝑄𝑐 , 𝑄𝑓 are the time-

averaged volumetric flow rate of the cells and fluid rate for water (37).  can be adjusted to control
the probability of encapsulating a specific number of cells within droplets (figure 2.3 and table
2.1). For instance, if =0.05, 95.13% of droplets will contain no cells (empty droplets), 4.76% of
droplets will contain only one cell and 0.12% of droplets will have more than a single cell. When
=0.5, 60.66% of droplets will be empty, 30.33% of droplets would contain one cell and 7.59% of
droplets would have two cells. If =1, 36.79% of droplets will be empty, 36.79% of droplets would
contain one cell, and 18.4% of droplets would contain two cells. When =2, 27% of droplets can
contain either one cell or two cells.
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Figure 2.3. Poisson distribution, p (𝜅 ,), provides the probability of encapsulating a given number of cells (𝜅) within single
droplets for a given cell concentration,  (0.05, 0.5, 1, 2).

Table 2.1. Probability p (𝜅,  ) of encapsulating a number of cells (𝜅) for various discrete values of average cell concentration,  .

Figure 2.4 shows us that when 𝜅 = 0, 𝑝(𝜅, 𝜆) displays an exponential decay, meaning that when
 value increases the probability of getting an empty droplet decreases, that is, more droplets would
contain cells. If  = 0, more than 95% of the droplets are empty and when  = 1, 37% of the
droplets would not contain any cell;  = 2, 13% of the total number of droplets are empty;  = 3,
approximately 6% of the total number of droplets would not contain cells. When 𝜅 = 1, and  =
1, 37% of the total number of droplets would contain one cell;  = 2, 27% of the total number of
droplets would contain a single cell;  = 3, approximately 13% of the droplets would contain one
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cell. When 𝜅 = 2, and  = 1, 18% of the total number of droplets would contain two cells;  = 2,
27% of the total number of droplets would contain two cells;  = 3, approximately 23% of the cells
would contain two cells. Therefore, as the  value increases, the probability distribution shifts
right, indicating that the likelihood of droplets containing one or more cells is higher when  value
is increased.

Figure 2.4. Poisson distribution p ( ,κ) with four discrete values of κ (0, 1, 2, 3) against several values of  .

Droplet microfluidics has grown significantly, mainly thanks to the implementation of an easily
accessible manufacturing technique, soft lithography, to fabricate microdevices using patterned
elastomeric polymers(39). Research and development on single cell analysis involving
microfluidic techniques has significantly increased over the last decade(40-42). Microfluidic
systems offer small volumes of reagents, dynamic reagent control, high-throughput,
biocompatibility and high sensitivity, which helped these systems to emerge as an important
enabling technology platform for the study of single cells. Microfluidics have several applications
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in single-cell research, such as PCR, isolation and culturing of cells, cytotoxicity, sorting,
separation, clone formation, lysis, gene and protein expression, and antibody secretion studies.
Most of the microfluidic systems used for analyzing single-cell behavior require spatial separation
or compartmentalization of cells in surface arrays or in two-phase systems, such as droplets(43).
Cell assays normally require multiple steps, such as compartmentalization, manipulation, and
measurement. Droplet microfluidics can integrate these steps and increase the throughput. Using
an inert carrier fluid, commonly oil, microfluidic devices can compartmentalize reactants by
encapsulating aqueous reagents in micron-sized droplets. These devices can generate
monodispersed droplets with a volume range of 0,05 pL to 1 nL or approximately 5 µm to 120 µm
in diameter(44). Small volumes conserve costly reagents, and high speeds greatly reduce the time
taken to evaluate extremely large libraries. Different materials could also be used to generate
picolitre-sized compartments, but an inert oil-water interface has the advantage of protecting
droplet contents from the microfluidic device walls. Accordingly, droplets eliminate fouling and
cross contamination, and multiple applications exemplify these advantages(45). Droplet
microfluidics can also often produce higher speeds by allowing the detection of reactions after
shorter time periods. If a single molecule or cell is present in a volume of 1 mL, its concentration
is extremely low. If that volume of 1 mL is emulsified into one million droplets, each 1 nL in
volume, one of these droplets may contain the single molecule or cell, and its concentration in the
droplet will increase by one million. As reaction rates rise with effective concentration, reaction
times which are normally on the order of hours in bulk can decrease to seconds or minutes within
droplets (46, 47). Therefore, the minimum concentration of reaction products needed for detection
will be more rapidly achieved in smaller volumes. Cells, DNA, and other particles or molecules in
the aqueous phase can be encapsulated within droplets. In fact, molecules, cells and particles can
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be encapsulated separately in individual droplets(48, 49). Microfluidic techniques can be merged
to conduct almost any biological reaction or experiment that can be performed on a traditional
microtiter well plate. Several of the most widely used assays in biological research have already
been demonstrated in microfluidic droplets. Small volumes, high speeds, low noise, and isolation
of droplet contents from solid surfaces and fluidic control are main reasons for using droplets
instead of well plates (45).
2.2

Droplet Microfluidics for Microbial Studies
Micro/nanotechnology and bacteriology may seem like two different worlds. Nevertheless,

the interaction between these two disciplines has developed a complex and quickly growing area
of research over the years. Several micro/nanotools have been developed to probe individual
bacteria and multi-species communities in diverse but very well-defined environments (35, 50).
Along with a number of exciting new technologies, the convergence of micro/nanotechnology and
bacteriology has given rise to new biological perspectives that would have been inaccessible
without these disciplines merged. Comprehending how bacteria assemble and function is a great
challenge, requiring an interdisciplinary approach. Typical sizes of a bacterial cell (0.5-3 µm)
correlate well with the length scales where micro and nanotechnology can shape and manipulate
the environment. Conventional methods for cultivating bacteria are incompatible with long-term
monitoring of an individual cell or the careful manipulation of its microenvironment. Microfluidics
and nanofabrication can develop well-defined chip ecosystems to research population-level
processes that replicate the sophistication of the natural environment(51). Droplets microfluidics
has the capability of generating, manipulating and monitoring droplets, which carry single cells or
small populations of bacteria. Therefore, these abilities open new approaches for solving problems
in diagnostics and for research on bacterial evolution. Effectively, droplet microfluidics emerged
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as one of the technological innovations that has provided new microbiological experimental
alternatives such as detecting and identifying pathogens, antibiotic susceptibility testing, microbial
physiology research, and biotechnological applications. Using droplets to study microorganisms
has several advantages over classical techniques such as bioreactors, flasks, Petri dishes and multiwell plates. The stochastic confinement of microorganisms in droplets, which is the process to
separate the whole sample into many small volumes so that the number of droplets exceeds the
number of cells, has the most significant advantage(52). The second most important aspect of
droplet microfluidics is the prospect of massively analyzing large numbers (even millions) of
individual droplets. The third most significant advantage is capability of carrying out more
complex experimental protocols involving iterative operations on droplets(50).
2.3

Methods
Microfluidic technology was applied to process a fluid sample containing bacteria with the aim of

encapsulating single bacterial cells within picoliter sized droplets. Equation 2.1 allow us to calculate the
theorical  value considering the desired number of bacterial cells in each droplet (k value). By determining
the original concentration of the suspension through culture methods, we can dilute the bacterial solution
based on the theorical  value and obtain the required bacterial concentration for encapsulation. After
calculating the total number of droplets generated (full and empty droplet) as well as the averaged volume
of the droplets, we can estimate the concentration of the original bacterial suspension. In this study, we
determine the  value by using the original bacterial suspension concentration based on culture methods
and the averaged droplet volume.

2.3.1

Microfluidic chip fabrication
Microfluidic biochips were manufactured in PDMS using standard soft lithography

procedures. SU-8 master molds with relief patterns of microchannels and flow-focusing geometry
were manufactured using photolithography on silicon wafers. The preparation of the substrate was
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conducted by cleaning the wafer with acetone and isopropyl on both sides 3-4 times and by drying
with air gun. The wafer was aligned on the spin coater and SU-8 was poured over the wafer. After
spinning at 3000 rpm for 30 seconds, a soft bake was performed at 65oC for 3 minutes and at 95 oC
for 9 minutes. Once the wafer cools down at room temperature, a UV exposure step was conducted
at 215mJ/cm2 for 12.8 seconds. Post exposure bake was done at 65 oC for 2 minutes and at 95oC
for 7 minutes. The wafer was immersed, swirled and agitated in a developer solution (1,2Propanediol mono-methyl ether acetate). After the master mold was silanized, PDMS was casted
over the master mold and baked at 75oC for 2 hours. Inlet and outlet holes were punched in the
PDMS. The PDMS slab is then peeled of the mold, and a microfluidic device is formed by bonding
it to a 75 x 50 x 1,2 mm glass microscope slide, using oxygen plasma for 60 seconds(53).
2.3.2

Microfluidic Experiments
All tubing, tools and syringes were sterilized with 70% (v/v) ethanol and all

solutions/mediums were autoclaved prior to use. The bacteria suspension and the oil were loaded
into gastight syringes with 27-gauge needles and infused into the device by using syringe pumps.
One pump injected bacteria solution through the inlet hole and the other pump injected oil through
two different holes. A fluorinated oil (Ethoxy fluorinated methyl alkane) from BIO-RAD was used
as the carrier phase for droplet generation. In order to harvest the droplets, the outlet tubing was
connected to a plastic vial. The filled vial was incubated and shaken at 37oC at 150 rpm for 8 hours
for bacterial growth.
2.3.3

Bacterial cell culture
Cells were obtained from ATCC [ E. Coli strain K-12 W3110 ATCC # 25923 (MSSA)].

Stock solutions of the bacterial cells were prepared by using Luria-Bertani (LB) medium Miller
formulation (BD, Sparks, MD) containing 10% (v/v) glycerol and stored at -80oC. A frozen stock
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vial was brought to room temperature for each experiment, streaked onto an agar plate and
incubated overnight at 37 oC. Single colonies from the plates were picked and transferred to LB
medium and grown in a shaker incubator at 37oC and 225 rpm for 4 hours until it reaches an OD600
of 1.0. OD measurements were performed by using Synergy H1 Hybrid Multi-Mode Microplate
Reader from Biotek Instruments. Then, cell density was adjusted to desired concentration by
diluting in LB prior to droplet encapsulation experiments. All procedures were performed in close
proximity to a Bunsen burner flame to maintain sterility, and all tubing, devices, flasks, syringes
and solutions used were either autoclaved or sterilized by EtOH 70% (v/v).
2.4
2.4.1

Results and Discussion
Bacterial Growth Curve
The relationship between time and number of cells is not linear but exponential during the

log phase; nevertheless, the growth curve is frequently plotted on a semilogarithmic graph, which
means the values on the y axis are logarithmic and gives us the impression of a linear relationship.
Once, the linear relationship is identified, we used several time points within the log phase to make
dilutions and obtain their respective CFU on agar plate with the objective of plotting OD
measurements versus cell concentration. Thus, this graph can be used to determine cell
concentration of a bacterial suspension based on OD measurements. After culturing bacterial cells
in 5ml of LB, a diluted solution was prepared (10X). A 20 L of the diluted bacterial suspension
was taken and mixed with 180L of LB. 18 of such aliquots (200L of sample per well) were
prepared in a 96-well plate. 129 absorbances were measured on the microplate reader at 600nm,
at 37oC, and double orbital shaking. The optical density measurements were obtained every 6.5
minutes for 16 hours. Unfortunately, this experiment was done once, and reproducibility
experiments were not possible.
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Figure 2.5. Optical density vs time measurements. Purple plot represents natural logarithm of OD’s vs time and green plot
represents OD values vs time.

The E. Coli growth curve is shown in figure 2.5. Bacterial cultures grow exponentially and the
growth rate is a change in the number of cells per minute, which is estimated as a change in OD
per minute(54). Here, since bacterial suspension was only diluted 10x, the lag phase was not
detected. It was necessary to obtain both plots in order to determine linearity in the log phase. As
a result, we determined that the bacterial growth was linear for OD values between OD = 0.1 and
OD = 0.6.
Colony Forming Units (CFU) was determined by performing serial dilutions of the cell
suspension. After diluting the bacterial solution 10 7x, a 100l of the suspension was spread on to
an LB agar plate and incubated overnight at 37 oC. This procedure was conducted twice for each
time point as well as optical density measurements at 50 min, 75 min, 100 min, 125 min, 150 min
respectively as displayed in figure 2.6.
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Figure 2.6. Optical density vs time (min) measurements to determine CFU in a cell suspension diluted 107 times.

After counting colonies, the CFU was calculated for each time point and plotted against their OD
values respectively. As a result, the linear regression equation is given as:
𝑦 = 2.0959 ∗ 10−11 ∗ 𝑥 + 0.1421

(2.5)

The below figure shows a fairly strong relationship (r2 = 0.9777) between the optical density
measurements and the bacterial cell concentration.

Figure 2.7. Correlation between bacterial cell concentration (bacteria cells/ml) and optical density
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2.4.2

Bacteria Encapsulation in Droplets
The microfluidic device was designed with a flow focusing geometry (see figure 2.1b). As

displayed in figure 2.8, the biochip contains three inlets, a main channel for injection of the
bacterial suspension, two inlet channels for the fluorinated oil injection, and one outlet channel.

Figure 2.8. Droplet microfluidic setup.

The depth of channels is 50 m, the top and bottom channels are 100 m wide. The width of the
middle channel is 60 m (see figure 2.9).

Figure 2.9. Microfluidic droplet device design.
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The bacterial solution was segmented into droplets by the shear flow of carrier fluorinated oil (see
figure 2.10). Droplets were produced using the flow rates 30 L/h and 90 L/h for aqueous and
oil phase, respectively. Droplets were collected into an Eppendorf tube for 1h and incubated in a
shaker incubator at 37 oC and 150 rpm for 4 hours and the droplets containing the bacteria are
imaged by a microscope (See Section 3.6).

Figure 2.10. Droplet generation by using device design from figure 2.9.

3
3.1

MACHINE LEARNING
Background
In 1950s, the field of artificial intelligence (AI) began when a number of pioneers from the

new field of computer science posed the question if machines can "think". A descriptive field
definition of artificial intelligence is as follows: an attempt to automate human intellectual work.
AI is a broad discipline that involves machine learning and deep learning. For quite a long time,
many experts believed that artificial intelligence at the human level could be achieved by having
programmers design a sufficiently large set of explicit rules for the manipulation of knowledge.
This approach is known as symbolic AI and from the 1950s until the end of the 1980s, it was the

28

dominant model for AI. For machine learning, human data and the predicted responses to the data
come from the rules. Such rules can then be used to produce original answers for new data. Several
examples are given to a task; and in these examples, it finds a mathematical framework that
essentially helps the system to establish rules for the automation of the task. This combination of
mathematics and computer science is motivated by the particular computational challenges in
constructing mathematical models from large data sets that can contain billions or trillions of data
points. The learning types used by computers can be categorized into two groups: supervised
learning and non-supervised learning.
3.2

Supervised Learning
Supervised learning begins with the objective of predicting a known output or target. It is

about mapping data to known targets, given a set of examples. Supervised learning emphasizes on
classification, which includes selecting among subsets to best describe a new instance of data and
predicting an unknown parameter(55). Some of the most important supervised learning algorithms
are k-Nearest Neighbors, Linear Regression, Logistic Regression, SVMs, Decision Trees and
Random Forests, and Neural Networks. The pattern recognition method uses Deep Neural
Networks (DNNs), which can help interpret medical tests, electrocardiograms, and vitals, and
recognize images from pathology specimens, retina, endoscopy, and skin lesions. The analysis of
a neural net is typically compared to the evaluation of medical professionals using a plot of truepositive against false-positive values, called Receiver Operating Characteristics (ROC), where the
region under a curve (AUC) is used to demonstrate the accuracy level(56). In a study using a broad
training dataset of nearly 130,000 digitized dermascopic images, at least 21 US board certified
dermatologists were matched in output by an algorithm that had an AUC of 0.96 specifically for
carcinoma and 0.94 specifically for melanoma(57). Another study involved a group of 58
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international dermatologists to measure the accuracy of melanoma skin cancer diagnosis with a
Convolutional Neural Network (CNN); the mean ROCs were 0.79 versus 0.86, respectively,
suggesting an increased algorithm efficiency compared to with health professionals (58). In a
whole-slide imaging (WSI) analysis of breast cancer, with or without metastasis of the lymph node,
which compared the output of 11 pathologists to that of various algorithmic interpretations, the
findings differed and were partly affected by the length of time the pathologists had to analyze the
slides. Some of the five algorithms did better than the team of pathologists, who had different
expertise. The pathologists obtained 129 test slides and had less than 1 minute per slide
examination, which is definitely not representative of usual workflow(59).
3.3

Unsupervised Learning
In comparison, there are no results that can be expected in unsupervised learning. Instead,

we seek to find patterns or groups within the data that occur naturally. It is basically a more difficult
task, and the importance of unsupervised learning in such groups is also assessed by its success in
subsequent supervised learning tasks. Some of the most important unsupervised learning
algorithms are k-Means, Principal Component Analysis (PCA), Expectation Maximization,
Hierarchical Cluster Analysis (HCA), and kernel PCA(55). From a technical point of view, while
supervised learning mainly addresses classification and regression problems, unsupervised
learning tackles more clustering and reduced dimensionality. Patterns identified in unsupervised
learning commonly need to be assessed for utility either by human interrogation or through
application within a supervised learning task. Clustering refers to defining groups within data,
supplying data to an algorithm, analyzing them and finding any implicit correlation within the data
that can be categorized into sub-sections and patterns within the data to be identified. Because of
the nature of the data and the heterogeneity of medical patients, intuition can make it difficult to
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classify groups, and the ability to elucidate such groups enables targeted diagnosis. Vranas et al.
analyzed a large data collection from an intensive care unit, where resource burden and outcomes
prediction were considerable challenges. Through evaluating patient variables retrospectively
using an unsupervised algorithm (clustering), they were able to classify patient subgroups with
substantially different clinical courses even with identical diagnoses, and by applying the
predictive clusters to a separate, unknown data set, the predictive power persisted(60).
3.4
3.4.1

Principle Machine Learning Algorithms for Medicine
Support Vector Machine
Support Vector Machine (SVM) is a supervised learning algorithm designed to divide data

into two or more categories. The term 'support vector' essentially refers to the margin used by the
algorithm to assess whether or not data is part of the group (see figure 3.1). Researchers often refer
to the use of 'kernels' in SVM, which are mathematical tools that modify data in certain ways to
make data more easily separated into categories(61). Although this is simple for two and threedimensional data sets, the power of the SVM is that it can be used for complex data sets with many
variables or dimensions. Because of its versatility, SVM has been implemented to a myriad of data
types, from the classification of presence/absence of micro-calcifications in breast mammograms,
to the classification of tissue and cell types based on genetic micro-array expression data (62, 63).
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Figure 3.1. Separation of two-dimensional data by Support Vector Machines

3.4.2

Neural Networks
Neural networks, also known as artificial NN, try to use multiple computation layers to

simulate the idea of how human brain interprets and draw conclusions from data. NNs are primarily
mathematical models designed to manage complex and diverse information; the nomenclature of
this algorithm is derived from the use of "nodes," similar to brain synapses (see figure 3.1). An
NN's learning process may either be supervised or unsupervised. The neural net is set up to learn
in a supervised manner if the desired output is already targeted and implemented to the network
by training data, while the unsupervised NN does not have such pre-identified target outputs and
the aim is to group similar units close together within a certain value range. The NN is used for
medical diagnostic purposes for both regular and variable data sets as well as data sets using
complex variables such as raw or transformed image data(64).
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Figure 3.2. Artificial Neural Network

3.4.3

Deep Learning
Deep learning is a particular machine learning subfield: a modern perspective on data

learning representations that emphasizes learning successive layers of progressively meaningful
representations. The difference between deep learning and a simple neural network is that the
number of node layers is increased, and the total size of the network is greater, allowing for more
accurate representation of complex interrelationships. To explain this, Convolutional Neural
Network (CNN), a form of feedforward NN designed to imitate neural processes within the brain,
is often applied to image processing tasks. CNNs are the cornerstone of all image-based deep
learning (see figure 3.2). The architecture allows nodes to connect to a part of the input image.
Convolutional blocks work within an image by moving along an image through a small window
area and generating the weighted sum of the pixel values for the filter in the region and applying
a non-linear transformation. Such convolutional layers are merged with pooling (subsampling)
layers, retrieving the most dominant values in the feature maps and reducing their resolution. The
loop is replicated several times until a particular resolution size of the filter map is obtained. In
essence, the early phases of the pipeline are programmed to resolve spatial data and convolutions
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serve as special feature detectors (e.g. edges, lines), ultimately teaching the network to connect
adjacent pixels in space. The result of these layers is a low-dimensional embedded representation
of an image which provides a much better representation of the image content than other methods
of feature-extraction(65, 66). A recent medical example of deep learning is the implementation of
a deep learning algorithm by Gulshan et al. to detect diabetic retinopathy from retinal fundus
images. Researchers took 128,175 retinal images that had already been studied by
ophthalmologists as their training set, built a deep learning algorithm that could analyze new
images and recognize diabetic retinopathy with 97.5 percent sensitivity and 93.4 percent
specificity(67).

Figure 3.3. Convolutional Neural Network

3.5
3.5.1

Methods
Data acquisition
Once the droplets were generated, a solution with two layers consisting of emulsion and

oil was collected into an Eppendorf tube at the outlet of the biochip. The Eppendorf tube, which
contains droplets with bacterial cells, was incubated for 4 hours at 150 rpm to allow bacterial cells
grow insight the droplets. Hence, this incubation allowed us to produce full droplets and obtain
droplet images to distinguish full and empty droplets. Then, 30 L of the upper layer, which
contains the emulsion with water-in-oil droplets, were taken and injected into a microfluidic flow
cell. The flow cell was made of two glass slides, sandwiched with two pieces of double-sided tape
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placed at the edges to form a capillary channel. Then, images of the microfluidic flow cell were
obtained by using an optical microscope (Nikon Eclipse Ti2) coupled with a CCD camera (Basler
acA1920-155um).
3.5.2

Data Analysis
Images were segmented by using ImageJ and Image Segmenter MATLAB App to analyze

the average droplet size and perform the initial classification steps. We have developed a
MATLAB script which inputs each image and classifies droplets containing bacteria as opposed
to empty droplets. For machine learning analysis, we used the Statistics and Machine Learning
Toolbox from MATLAB.
3.6
3.6.1

Results and Discussion
Image Analysis for Droplet Size
Images were acquired by using 6x phase contrast objective lens. To segment the images

for droplet size analysis, the Triangle algorithm of Image J was chosen to perform thresholding to
divide each image into two or more-pixel classes. Based on the camera specifications, the pixel
size (H x V) is 5.86 m; therefore, the distance in pixels was set at 0.9767 pixels/m. The average
area of the droplets was approximately 3400 m2; thus, we calculated the average diameter of the
droplets to be 65.5 m.
3.6.2

Measure Bacteria Biomass with Poisson Distribution
When encapsulating bacteria cells into droplets, the cell number distribution in droplets

follows Poisson statistics. Equation 2.1 estimates the fraction of droplets containing  number of
bacteria cells, with a given mean bacterial concentration for per droplet volume (). In this work,
a bacterial suspension was prepared, and optical density measurements were taken four times
which have an average of ̅̅̅̅
𝑂𝐷 = 1.045. Replacing this value in equation 2.5, the approximate
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concentration of the bacterial suspension (C) would be 4.3079 x 1010 cells/mL. Equation 2.1
defined  as the average number of cells per droplet volume; therefore, we can deduce  = C ∗
𝑉𝑑 (2.6), where C can be defined as the number of bacteria cells per mL and 𝑉𝑑 as the average
of droplet volume. By using the average diameter of the droplets, 𝑉𝑑 value would be 1.47 x 10 -7
mL. Hence, the value of  for this experiment would be 6333.14, which would represent the
average number of cells per droplet for this study. These results rely on measuring the initial
bacteria concentration through a combination of OD600 and CFU measurements and tend to
overestimate the initial concentration of bacteria in the original sample. While a  value as high as
6333.14 warrants all droplets containing bacteria, the experimental data suggests otherwise (see
Section 3.6.3 below), confirming that the original bacteria concentration is overestimated by
conventional methods.
3.6.3

Image Segmentation for Droplet Classification
Images were segmented by using the adaptive threshold algorithm of MATLAB App and

closed masks were created with a morphology shape- disk with a radius of 3. Also, droplets that
touched the borders of the images were not included in the analysis as depicted in figure 3.4.
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a)

b)

Figure 3.4 a) and b) are images obtained as a result of the experiments. Left images show full droplets, which are those with the
contrasting circles in their inner background. Conversely, empty droplets are those circles whose inner background is black. The
right images are the corresponding segmentation of the left images.

3.6.4

Image Classification by IBA
After segmentation, statistical analysis of the droplets was performed based on major axis

length, circularity, and perimeter properties to identify the centroids of the droplets. As shown in
figure 3.5, we assumed that values lower than 20 pixels and greater than 80 pixels of the major
axis lengths could be considered noise. However, we observed fewer artefacts with centroids and
large droplets removed from the analysis when we set the range between 50 pixels and 70 pixels.
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Figure 3.5. Histogram: Major Axis Length of Droplets

The circularity value for a perfect circle is 1; therefore, we could remove all the values greater than
1.0. We could see in figure 3.6 that most of the values were between 0.9 and 1.0. Nevertheless, we
were able to identify more droplets with centroids between 0.7 and 1.0.

Figure 3.6. Histogram: Circularity of Droplets

Analyzing the histogram of the perimeter values as displayed in figure 3.7, we observed that the
range between 150 pixels and 250 pixels contained most of the perimeter values.
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Figure 3.7. Histogram: Perimeter of droplets

When we applied all these properties as exclusion criteria, we could identify >97% of the centroids
of the droplets. Furthermore, we set a square of 20 pixels (H x V) around each centroid in order to
determine the mean and the median of intensity of the pixels of each square. As shown in figure
3.8, full droplets are displayed with yellow squares and empty droplets with blue squares.

Figure 3.8. Droplet Classification of figure 3.4a. Yellow squares represent full droplets and blue squares represent empty droplets.

As a result, the total number of droplets identified by the algorithm was 352, 164 of which
corresponded to full droplets (47 %) and 188 empty droplets (53 %).
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3.6.5

Image Classification by Support Vector Machines
In addition to the previous algorithm, we used Support Vector Machines to classify full

droplets and empty droplets. As we had a low dimensional dataset, we chose fitcsvm, which is the
Train Support Vector Machine classifier used for binary classification. 338 cropped droplet images
were obtained from figure 3.4b and a squared area (20 pixels x 20 pixels) around the centroid of
each droplet was used to create our model. The size of the training and test dataset was 320 and
18, respectively. Figure 3.9 shows the confusion matrix for our trained model when we used the
test dataset and all the 18 images were classified 100% correctly.

Figure 3.9. Confusion matrix to evaluate training of SVMs for droplets of figure 3.4b.

After training, we used our model to classify 356 cropped squared images (20 pixels x 20 pixels)
from figure 3.4a, which contains 191 empty droplets and 165 full droplets. As displayed in figure
3.10, 187 droplets were correctly classified as empty droplet and 6 empty droplets were
misclassified as full droplets. This corresponds to 52.4 % and 1.7 %, respectively, of all 356
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droplets. Furthermore, the model classified 159 droplets correctly as full and misclassified 4 full
droplets as empty. This corresponds to 44.7 % and 1.1 %, respectively, of the total number of
droplets. Out of 193 empty droplet predictions, 96.9 % were correct and 3.1 % were incorrect.
Additionally, out of 163 full droplet predictions, 97.5 % were correct and 2.5 % were incorrect.
Hence, out of 191 empty droplets, 97.9 % were correctly predicted as empty and 2.1 % were
predicted as full. Out of 165 full droplet cases, 96.4 % were correctly predicted as full and 3.6 %
were classified as empty. Overall, 97.2 % of the predictions were correct and 2.8 % were incorrect.

Figure 3.10. Confusion matrix to evaluate binary classification accuracy of SVMs for droplets of figure 3.4a.

4

CONCLUSIONS AND FUTURE WORK
In this work, we have proposed a technology based on microfluidics and machine learning to

quantify the bacteria in a liquid sample. Our platform breaks the sample into tiny picoliter droplets
while encapsulating bacteria within the sample, cultures the bacteria within the emulsion using
conventional incubation techniques, allowing the bacteria to populate the droplet, then classifies
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the droplets that contain bacteria as full and those that do not contain bacteria as empty droplets.
As a result, we obtain a quantitative population-level representation of the emulsified bacterial
colonies, following Poisson statistics, which allows us to accurately estimate the initial bacterial
concentration in the original sample. In order to accomplish our goal, we conducted experiments
that allowed us to determine the original concentration of the bacterial suspension to calculate 
value, which is the average number of bacterial cells per droplet. In chapter 2, we described the
validated methods and protocols that we used to obtain the concentration of the bacterial solution.
In chapter 3, we described the image processing methods as well as the machine learning
algorithms (supervised model based on support vector machines) to classify full and empty
droplets. Our results showed that our proposed algorithm (IBA) identified and classified full and
empty droplets correctly based on a dataset acquired from droplet images provided in figure 3.4
and 3.5. By using the same dataset, our trained SVM model correctly classified 97.2% of the
images and only 2.8 % of the images was classified incorrectly.
Unfortunately, reproducibility for the culture method could not be evaluated; therefore, the 
value of the bacterial suspension could be lower than the calculated  value for this study. It is also
possible that the number of full and empty droplets could have been different if reproducibility
experiments for droplet microfluidics had been conducted. Even if we would have the
reproducibility evaluation, it is likely that the culture method could be still overestimating the 
value as compared to that of Poisson distribution. These limitations can be overcome in the future
by conducting three or five experiments to assess reproducibility for both the culture method and
the droplet microfluidics.
Nevertheless, these findings have provided valuable information to propose further research
in quantitative microbiology. For instance, a new model in machine learning can be trained by
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using images of incubated droplets at 50 min, 75 min, 100 min, 125 min, and 150 min to classify
full and empty droplets through Convolutional Neural Network algorithm. By doing this research,
we could improve speed and accuracy for bacterial quantification and detection. Another future
study could evaluate the performance of our proposed model with droplets containing different
concentration of bacteria cells along with different types of bacteria by using deep learning
algorithm. Therefore, this research describes the fundamental principles of a technology that offers
a versatile tool to detect and quantify bacterial cells in biomedical fields where rapid and accurate
detection of bacteria is vital.
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